% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • redhot47fla redhot47fla Nov 5, 2012 12:38 PM Flag

    Upcoming ASH studies: Adcetris + AVD achieves 92% complete remission rate in front-line Hodgkin and strong response in non-Hodg

    The rest of the post (man, Yahoo has messed up these boards):

    ...CD30 expression levels for patients with a CR or PR were widely variable and ranged from

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • And, if you go to Seattle Genetics' website, you can see the ASH-related press release the company just posted, somewhat tardily:

      Seattle Genetics’ ASH 2012 Presentations Highlight ADCETRIS® and Demonstrate Leadership in the Development of Antibody-Drug Conjugates (ADCs)

      -Data Support Plans to Establish ADCETRIS as the Foundation of Therapy for a Broad Array of CD30-Positive Malignancies-

      -Company Announces Novel ADC Candidate SGN-CD33A and Encouraging ADC Collaborator Data Presentations-

      BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 5, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that more than a dozen abstracts, in addition to several collaborator abstracts, for both ADCETRIS (brentuximab vedotin) and investigational antibody-drug conjugates (ADCs) will be presented at the American Society of Hematology (ASH) Annual Meeting taking place in Atlanta, Georgia, December 8 – 11, 2012. ADCETRIS is an ADC directed to CD30, which is known to be expressed in Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL), as well as in some types of cutaneous T-cell lymphoma (CTCL), B-cell lymphomas and mature T-cell lymphomas (MTCL). Seattle Genetics is broadly evaluating CD30 expression in many other cancer types. ADCETRIS is currently not approved for use in CTCL, B-cell lymphomas, and front-line treatment of HL or MTCL....

42.76+0.55(+1.30%)10:56 AMEST